{"name":"Italian Sarcoma Group","slug":"italian-sarcoma-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"ADM","genericName":"ADM","slug":"adm","indication":"Soft tissue sarcoma","status":"marketed"},{"name":"CYC","genericName":"CYC","slug":"cyc","indication":"Sarcoma (various histologies)","status":"marketed"},{"name":"VIN","genericName":"VIN","slug":"vin","indication":"Hodgkin lymphoma","status":"marketed"},{"name":"ETO","genericName":"ETO","slug":"eto","indication":"Small cell lung cancer","status":"marketed"},{"name":"IFO","genericName":"IFO","slug":"ifo","indication":"Testicular Germ Cell Tumor","status":"marketed"},{"name":"Intensified chemotherapy","genericName":"Intensified chemotherapy","slug":"intensified-chemotherapy","indication":"High-risk or metastatic soft tissue sarcoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"BUMEL","genericName":"BUMEL","slug":"bumel","indication":"Other","status":"phase_2"},{"name":"Mifamurtide arm","genericName":"Mifamurtide arm","slug":"mifamurtide-arm","indication":"Other","status":"phase_2"},{"name":"TEMIRI","genericName":"TEMIRI","slug":"temiri","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ADM","genericName":"ADM","slug":"adm","phase":"marketed","mechanism":"ADM (doxorubicin) is an anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death.","indications":["Soft tissue sarcoma","Bone sarcoma","Various solid tumors and hematologic malignancies"],"catalyst":""},{"name":"CYC","genericName":"CYC","slug":"cyc","phase":"marketed","mechanism":"CYC is a cyclophosphamide-based chemotherapy agent that alkylates DNA to inhibit cancer cell proliferation.","indications":["Sarcoma (various histologies)","Soft tissue sarcoma","Bone sarcoma"],"catalyst":""},{"name":"VIN","genericName":"VIN","slug":"vin","phase":"marketed","mechanism":"VIN (vinblastine) is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in rapidly dividing cells.","indications":["Hodgkin lymphoma","Non-Hodgkin lymphoma","Testicular cancer","Breast cancer","Lung cancer"],"catalyst":""},{"name":"BUMEL","genericName":"BUMEL","slug":"bumel","phase":"phase_2","mechanism":"BUMEL combines two alkylating agents that damage DNA and prevent cancer cell replication.","indications":[],"catalyst":""},{"name":"ETO","genericName":"ETO","slug":"eto","phase":"marketed","mechanism":"ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death.","indications":["Small cell lung cancer","Testicular cancer","Lymphomas","Leukemias","Sarcomas"],"catalyst":""},{"name":"IFO","genericName":"IFO","slug":"ifo","phase":"marketed","mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis.","indications":["Testicular Germ Cell Tumor"],"catalyst":""},{"name":"Intensified chemotherapy","genericName":"Intensified chemotherapy","slug":"intensified-chemotherapy","phase":"phase_3","mechanism":"Intensified chemotherapy uses higher doses or more aggressive combinations of cytotoxic agents to maximize tumor cell kill in sarcoma patients.","indications":["High-risk or metastatic soft tissue sarcoma","Osteosarcoma"],"catalyst":""},{"name":"Mifamurtide arm","genericName":"Mifamurtide arm","slug":"mifamurtide-arm","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TEMIRI","genericName":"TEMIRI","slug":"temiri","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPVUtpT3ktTURvZ1NCNEo5Z1RyOU5PVlh4ejRoajVoWDNmbkRWT3VpVFF1Q0xoQWNTRG8xWmlhYUFKa2dhS1FBUGFFcVdrOW5HQ2trZHRjSHdzY2dPLTN1bm9ucnNKLUV5T3JMTFZZRFpYQ3pvWVYyRlQxTXVjekM2cnA5VGs4N0tBME5oVzVKcXYtdHpw?oc=5","date":"2025-12-22","type":"pipeline","source":"The American Journal of Managed Care® (AJMC®)","summary":"Trabectedin Plus Olaparib Improves PFS in Some Patients With STS - The American Journal of Managed Care® (AJMC®)","headline":"Trabectedin Plus Olaparib Improves PFS in Some Patients With STS - The American Journal of Managed Care® (AJMC®)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5ZUlVUZVBsZTI2VVp6V0Rkc3pGMUhPYjFHOE9GblRzUzRQQ3hZT2xsWTBpZ1dxX2Utdlk1Q2xXOFBKeUo1T2lSVzlZOC00R3ZOMmNCOEgtLVQzZjBWQmFPVW5wQ2FVbGF4V3M0a1hBUkxBUDdnNUpmV24zUQ?oc=5","date":"2023-08-02","type":"trial","source":"Wiley","summary":"Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) - Wiley","headline":"Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 S","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":5,"phase_2":3,"phase_3":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}